Discovering The Potential of Zeb1 as A Drug Target and Biomarker

Target Name: ZEB1

NCBI ID: G6935

ZEB1

Discovering The Potential of Zeb1 as A Drug Target and Biomarker

Zeb1, a transcription factor 8 (TF8), is a protein that plays a crucial role in regulating gene expression and has been associated with various diseases. Zeb1 has been shown to be a potential drug target and biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In this article, we will discuss the biology of Zeb1, its functions, and its potential as a drug target.

Background

Zeb1 is a non-coding RNA-protein hybrid that contains a unique N-terminal region composed of 19 non-coding amino acids and a C-terminal region composed of 15 non-coding amino acids. Zeb1 is expressed in various tissues and cells of the body and has been shown to play a role in various physiological processes, including cell growth, differentiation, and inflammation.

Function

Zeb1 is a key transcription factor that has been shown to regulate the expression of numerous genes. Zeb1 has been shown to promote the expression of genes involved in cell adhesion, migration, and invasion. Zeb1 has also been shown to play a role in the regulation of cell apoptosis, which is a critical mechanism that helps maintain tissue homeostasis and remove damaged or dysfunctional cells.

In addition to its role in cell regulation, Zeb1 has also been shown to be involved in the development and progression of various diseases. For example, Zeb1 has been shown to be involved in the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Zeb1 has also been shown to be involved in the development of cancer, including breast cancer.

Potential as a drug target

The potential of Zeb1 as a drug target is based on its involvement in various diseases and its ability to regulate gene expression. Zeb1 has been shown to be involved in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Therefore, Zeb1 may be a potential drug target for these diseases.

Zeb1 has also been shown to be involved in the development of cancer, including breast cancer. Therefore, Zeb1 may also be a potential drug target for cancer.

In addition to its potential as a drug target, Zeb1 has also been shown to be a biomarker for various diseases. For example, Zeb1 has been shown to be involved in the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Therefore, Zeb1 may be a useful biomarker for these diseases.

Conclusion

In conclusion, Zeb1 is a transcription factor that plays a crucial role in regulating gene expression and has been associated with various diseases. Zeb1 has been shown to be a potential drug target and biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Further research is needed to fully understand the role of Zeb1 in disease and its potential as a drug target.

Protein Name: Zinc Finger E-box Binding Homeobox 1

Functions: Acts as a transcriptional repressor. Inhibits interleukin-2 (IL-2) gene expression. Enhances or represses the promoter activity of the ATP1A1 gene depending on the quantity of cDNA and on the cell type. Represses E-cadherin promoter and induces an epithelial-mesenchymal transition (EMT) by recruiting SMARCA4/BRG1. Represses BCL6 transcription in the presence of the corepressor CTBP1. Positively regulates neuronal differentiation. Represses RCOR1 transcription activation during neurogenesis. Represses transcription by binding to the E box (5'-CANNTG-3'). Promotes tumorigenicity by repressing stemness-inhibiting microRNAs

The "ZEB1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZEB1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets